TG THERAPEUTICS (TGTX) Company Report

TG Therapeutics reported total global revenue of approximately $616 million for the full year 2025, driven by $594 million in BRIUMVI U.S. net sales. The company achieved $183 million in U.S. net sales for Q4 2025, representing approximately 92% year-over-year growth and 20% sequential growth from Q3.
For the full year 2025, TG Therapeutics recorded net income of $447.2 million, or $2.77 per diluted share, which included a non-recurring income tax benefit of approximately $340 million.
The company provided full-year 2026 guidance for U.S. Breyanzi net revenue of $825 million-$850 million and total global revenue of $875 million-$900 million. For Q1 2026, U.S. revenue is expected to be approximately $185 million-$190 million.
Key pipeline updates include the completed enrollment for the Phase III ENHANCE study, with top-line data expected mid-2026 and a potential 2027 launch. The Phase 3 study for subcutaneous BRIUMVI is approximately 75% enrolled, targeting pivotal top-line data later in 2026 or early 2027, with a potential 2028 launch.
TG Therapeutics completed its initial $100 million share repurchase program and the board authorized an additional $100 million program, reflecting continued confidence in the company's long-term outlook.

1 day ago

Transcript

TG Therapeutics Reports Strong FY 2025 Results and Provides 2026 Guidance

TGTX

Earnings

Guidance Update

Share Buyback

TG Therapeutics reported FY 2025 global revenue of approximately $616 million, with $594 million from BRIUMVI U.S. net sales, and Q4 2025 U.S. net sales of $183 million, representing 92% year-over-year growth.
The company reaffirmed its FY 2026 U.S. BRIUMVI net revenue guidance of $825 million-$850 million and total global revenue guidance of $875 million-$900 million.
Key pipeline updates include expected top-line data for the ENHANCE study (consolidated BRIUMVI infusion) by mid-2026 for a potential 2027 launch, and pivotal top-line data for the subcutaneous BRIUMVI program by late 2026 or early 2027 for a potential 2028 launch.
TG Therapeutics completed a $100 million share repurchase program and the board authorized an additional $100 million program, reflecting confidence in the long-term outlook and expected positive cash flow in 2026 and beyond.

1 day ago

Transcript

TG Therapeutics Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Updates Pipeline

TGTX

Earnings

Guidance Update

New Projects/Investments

TG Therapeutics reported total global revenue of $616 million for the full year 2025, with $594 million from BRIUMVI U.S. net sales, and $183 million in BRIUMVI U.S. net sales for Q4 2025. The company achieved $123 million in operating income and $447.2 million in net income for the full year 2025, which included a $340 million non-recurring income tax benefit.
For 2026, the company reaffirmed its guidance for U.S. BRIUMVI net revenue of $825 million-$850 million and total global revenue of $875 million-$900 million. Q1 2026 U.S. revenue is expected to be approximately $185 million-$190 million.
The Phase 3 ENHANCE study, evaluating a consolidated BRIUMVI treatment schedule, has completed enrollment, with top-line data expected mid-year 2026 and a potential 2027 launch. The Phase 3 study for a self-administered, at-home subcutaneous BRIUMVI is approximately 75% enrolled, targeting pivotal top-line data later in 2026 or early 2027, with a potential 2028 launch.
The company completed its initial $100 million share repurchase program and authorized an additional $100 million program. TG Therapeutics anticipates generating positive cash flow in 2026 and beyond.

1 day ago

Transcript

TG Therapeutics Reports Q4 and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TGTX

Earnings

Guidance Update

Share Buyback

TG Therapeutics reported total revenue of $192.6 million for Q4 2025 and $616.3 million for the full year 2025, with BRIUMVI U.S. net revenue of $182.7 million and $594.1 million respectively.
The company issued 2026 financial guidance, projecting total global revenue of approximately $875-$900 million, including BRIUMVI U.S. net product revenue of approximately $825-$850 million.
Net income for full year 2025 was $447.2 million, significantly boosted by a $339.8 million non-recurring income tax benefit in Q3 2025.
TG Therapeutics completed a $100 million share repurchase program in Q3 2025 and authorized a new $100 million program.

1 day ago

8-K

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and 2026 Guidance

TGTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

TG Therapeutics reported total revenue of $192.6 million for the fourth quarter of 2025 and $616.3 million for the full year 2025. This includes BRIUMVI U.S. net revenue of $182.7 million for Q4 2025 and $594.1 million for the full year 2025, representing approximately 92% growth year over year.
The company achieved net income of $23.0 million for the three months ended December 31, 2025, and $447.2 million for the twelve months ended December 31, 2025, with the full year results including a non-recurring income tax benefit of approximately $339.8 million.
For 2026, TG Therapeutics provided target guidance of approximately $875-$900 million in total global revenue, with BRIUMVI U.S. net product revenue expected to be approximately $825-$850 million.
As of December 31, 2025, cash, cash equivalents, and investment securities totaled $199.5 million.
The company completed a $100 million share repurchase program in the third quarter of 2025, purchasing approximately 3.5 million shares at an average price of $28.55 per share, and authorized a new $100 million share repurchase program.

1 day ago

Press Release

TG Therapeutics Publishes Positive 5-Year BRIUMVI Data in JAMA Neurology

TGTX

TG Therapeutics announced the publication of five-year data from the Phase 3 ULTIMATE I and II studies for BRIUMVI (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS) in JAMA Neurology on February 17, 2026.
The long-term evaluation demonstrated durable clinical efficacy, with the annualized relapse rate (ARR) for continuous BRIUMVI treatment decreasing to 0.020 in Year 5, equivalent to one relapse every 50 years of patient treatment.
The study also confirmed a consistent safety profile for BRIUMVI over five years of continuous treatment, with no new safety signals emerging with prolonged use.
These findings represent a major milestone for TG Therapeutics and the MS field, supporting BRIUMVI's continued role as a valuable treatment option for people with relapsing MS.

Feb 17, 2026, 12:30 PM

Press Release

TG Therapeutics Reviews 2025 Performance and Provides 2026 Guidance at J.P. Morgan Healthcare Conference

TGTX

Guidance Update

Product Launch

Revenue Acceleration/Inflection

TG Therapeutics reported $616 million in total global revenues for 2025, with $594 million from Briumvi U.S. net revenue, representing 90% year-over-year growth. The company projects 2026 global net revenue to be between $875 million and $900 million, with U.S. net revenue for Briumvi expected to be $825 million to $850 million.
Briumvi has achieved approximately one-third market share in the HCP-administered anti-CD20 portion of the MS market and an overall 20% total market share, driven by its "best-in-class" product, team, and competitive pricing as the lowest-priced branded MS treatment.
Key pipeline developments include a consolidated IV dosing for Briumvi with top-line data expected mid-2026 and a target launch in 2027, and a self-administered subcutaneous (subcu) Briumvi with top-line data expected late 2026/early 2027 and a target launch in 2028. The subcu formulation is expected to significantly expand the total addressable market.
The company holds patents for Briumvi into the mid-2040s, including a composition of matter patent through 2042/2043 and a subcu formulation patent through 2045, supporting long-term growth. TG Therapeutics also has $100 million in capacity under its stock repurchase plan and is likely to increase share repurchases.

Jan 13, 2026, 9:30 PM

Transcript

TG Therapeutics Highlights Strong BRIUMVI Performance and Outlines 2026 Growth Strategy

TGTX

Guidance Update

Revenue Acceleration/Inflection

Product Launch

TG Therapeutics reported ~$616 million in Total Global Revenue for FY 2025, with BRIUMVI U.S. Net Revenue reaching ~$594 million. The company projects FY 2026 Total Global Net Revenue of ~$875-900 million and BRIUMVI U.S. Net Revenue of ~$825-850 million.
The company is pursuing significant market expansion with planned launches of IV BRIUMVI consolidated dosing schedule in 2027 and SubQ BRIUMVI in 2028, aiming to address distinct patient segments.
Key R&D goals for 2026 include announcing pivotal topline data for the ENHANCE trial (mid-2026) and subcutaneous BRIUMVI (YE26/1Q27), along with presenting preliminary Phase 1 azer-cel data in Progressive MS (2H 2026).
BRIUMVI is the first and only anti-CD20 for Relapsing forms of Multiple Sclerosis (RMS) delivered in a 1-hour infusion every 6 months after the starting dose, and has been rapidly adopted by over 97% of top 200 MS Centers.

Jan 13, 2026, 9:30 PM

Presentation

TG Therapeutics Reports Strong 2025 Revenue and Provides 2026 Guidance with Key Pipeline Updates

TGTX

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

TG Therapeutics reported $616 million in total global revenues for 2025, including $594 million from Briumvi U.S. net revenue, marking approximately 90% year-over-year growth. Cumulative Briumvi revenues reached $992 million by the end of 2025 and exceeded $1 billion in early 2026.
The company provided 2026 guidance, targeting global net revenue of approximately $875 million to $900 million and Briumvi U.S. net revenue of $825 million to $850 million. Core operating expenses (R&D and SG&A) are projected around $350 million.
Significant pipeline milestones for 2026 include anticipated top-line data for consolidated IV dosing of Briumvi by mid-year (with a target launch in 2027) and for subcutaneous Briumvi by late 2026 or early 2027 (with a target launch in 2028). The subcutaneous formulation is expected to substantially increase Briumvi's total addressable market.
TG Therapeutics plans to initiate a registration-directed trial for Briumvi in a new indication outside of MS in 2026 and expects data from its Azer-cel progressive MS cohort this year. The company also has $100 million capacity under its share repurchase plan, with a potential for increase.

Jan 13, 2026, 9:30 PM

Transcript

TG Therapeutics Provides 2026 Revenue Guidance and Updates on Briumvi Performance and Pipeline

TGTX

Guidance Update

Product Launch

Revenue Acceleration/Inflection

TG Therapeutics reported $616 million in total global revenues for 2025, with $594 million from Briumvi U.S. net revenue, marking approximately 90% year-over-year growth.
The company provided 2026 guidance, targeting global net revenue of approximately $875 million to $900 million and Briumvi U.S. net revenue of $825 million to $850 million. Core operating expenses (R&D and SG&A) are projected around $350 million.
Briumvi, an anti-CD20 for multiple sclerosis, has achieved approximately one-third market share in the HCP-administered segment and about 20% total market share, with a goal to become the number one prescribed anti-CD20.
Upcoming product developments include a consolidated IV dosing for Briumvi, with top-line data expected mid-2026 and a target launch in 2027, and a self-administered subcutaneous (subcu) Briumvi, with top-line data expected late 2026/early 2027 and a target launch in 2028.
The pipeline also includes Azer-cel, a CD19 CAR-T product for progressive MS, with data expected in 2026. Briumvi's patent protection extends into the mid-2040s, including a subcu formulation patent through 2045.